BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sato K, Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases 2016; 4(3): 88-93 [PMID: 26989674 DOI: 10.12998/wjcc.v4.i3.88] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Rostaing L, Alric L, Kamar N. Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. Transpl Int 2016;29:1257-65. [DOI: 10.1111/tri.12870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
2 Fabrizi F, Donato FM, Messa P. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis. Int J Artif Organs 2017;40:531-41. [PMID: 28708211 DOI: 10.5301/ijao.5000613] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS One. 2016;11:e0163884. [PMID: 27684567 DOI: 10.1371/journal.pone.0163884pone-d-16-27137] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96 [PMID: 30148074 DOI: 10.5500/wjt.v8.i4.84] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS One. 2016;11:e0163884. [PMID: 27684567 DOI: 10.1371/journal.pone.0163884] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang HC, Ren YP, Qiu Y, Zheng J, Li GL, Hu CP, Zhou TY, Lu W, Li L. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. Acta Pharmacol Sin 2018;39:140-53. [PMID: 28880015 DOI: 10.1038/aps.2017.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Takakusagi S, Sato K, Suzuki Y, Yamazaki Y, Kosone T, Kakizaki S, Kusano M, Takagi H. Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia. Intern Med 2018;57:2189-95. [PMID: 29526955 DOI: 10.2169/internalmedicine.9624-17] [Reference Citation Analysis]